- 全部删除
您的购物车当前为空
Alogliptin Benzoate (SYR 322) 是一种有效且特异性的 DPP-4 抑制剂 ,IC50值小于 10 nM,其选择性比 DPP-8/9 高 10,000 倍以上,可用于研究 2 型糖尿病。

Alogliptin Benzoate (SYR 322) 是一种有效且特异性的 DPP-4 抑制剂 ,IC50值小于 10 nM,其选择性比 DPP-8/9 高 10,000 倍以上,可用于研究 2 型糖尿病。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 196 | In stock | |
| 5 mg | ¥ 388 | In stock | |
| 10 mg | ¥ 496 | In stock | |
| 25 mg | ¥ 736 | In stock | |
| 50 mg | ¥ 993 | In stock | |
| 100 mg | ¥ 1,390 | In stock | |
| 200 mg | ¥ 1,980 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 396 | In stock |
Alogliptin Benzoate 相关产品
| 产品描述 | Alogliptin Benzoate (SYR 322)(SYR 322), an effective and specific DPP-4 inhibitor (IC50<10 nM), exhibits greater than 10, 000-fold selectivity over DPP-8/9. Alogliptin may inhibit inflammatory responses by preventing the toll-like receptor 4 (TLR-4)-mediated formation of proinflammatory cytokines. |
| 靶点活性 | DPP4:<10 nM |
| 体外活性 | Alogliptin(SYR-322)是一种高效的DPP-4抑制剂,对与其密切相关的丝氨酸蛋白酶DPP-8和DPP-9的选择性超过10,000倍。Alogliptin不抑制CYP-450酶,且在高达30μM的浓度下不阻断hERG通道。[1] |
| 体内活性 | Alogliptin(SYR-322)在女性Wistar肥胖大鼠体内产生剂量依赖性地改善葡萄糖耐受性,并增加血浆胰岛素水平。[1] Alogliptin的急性给药能显著降低血浆DPP-4活性,并增加血浆活性GLP-1水平。Alogliptin在0.3 mg/kg及更高剂量时改善葡萄糖耐受性,伴随血浆IRI剂量依赖性增加,表明通过增强胰岛素分泌的能力来改善葡萄糖耐受性。[2] |
| 别名 | 苯甲酸阿格列汀, SYR 322, Alogliptin(SYR-322)benzoate |
| 分子量 | 461.51 |
| 分子式 | C25H27N5O4 |
| CAS No. | 850649-62-6 |
| Smiles | Cn1c(=O)cc(n(c1=O)Cc1ccccc1C#N)N1CCC[C@H](C1)N.c1ccc(cc1)C(=O)O |
| 密度 | no data available |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 55 mg/mL (119.17 mM), Sonication is recommended. Ethanol: < 1 mg/mL (insoluble or slightly soluble) H2O: 2 mg/mL (4.33 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||||||||||||
H2O/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||
评论内容